deltatrials
Completed PHASE3 NCT00004054

Hormone Therapy Plus Radiation Therapy With or Without Combination Chemotherapy in Treating Patients With Prostate Cancer

A Phase III Protocol of Androgen Suppression (AS) and Radiation Therapy (RT) vs AS and RT Followed by Chemotherapy With Paclitaxel, Estramustine, and Etoposide (TEE) for Localized, High-Risk, Prostate Cancer

Sponsor: National Cancer Institute (NCI)

Conditions Prostate Cancer
Interventions Luteinizing hormone releasing hormone [LHRH] agonist Radiation therapy bicalutamide estramustine phosphate sodium etoposide flutamide paclitaxel warfarin
Updated 11 times since 2017 Last updated: Oct 19, 2020 Started: Jan 31, 2000 Primary completion: Apr 30, 2010 Completion: Nov 30, 2013

A PHASE3 clinical study on Prostate Cancer, this trial is completed. The trial is conducted by National Cancer Institute (NCI) and has accumulated 11 data snapshots since 2000. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Change History

11 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE3

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE3

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE3

  4. Jan 2023 — Jul 2024 [monthly]

    Completed PHASE3

  5. Dec 2022 — Jan 2023 [monthly]

    Completed PHASE3

▶ Show 6 earlier versions

  1. Jan 2021 — Dec 2022 [monthly]

    Completed PHASE3

  2. Nov 2020 — Jan 2021 [monthly]

    Completed PHASE3

  3. Dec 2019 — Nov 2020 [monthly]

    Completed PHASE3

  4. Jun 2018 — Dec 2019 [monthly]

    Completed PHASE3

  5. Feb 2017 — Jun 2018 [monthly]

    Completed PHASE3

  6. Jan 2017 — Feb 2017 [monthly]

    Completed PHASE3

    First recorded

Jan 2000

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • National Cancer Institute (NCI)
  • Radiation Therapy Oncology Group
Data source: Radiation Therapy Oncology Group

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Akron, United States, Allentown, United States, Ann Arbor, United States, Annapolis, United States, Baltimore, United States, Baton Rouge, United States, Bethlehem, United States, Birmingham, United States, Columbia, United States, Columbus, United States and 38 more location s